Skip to content

JUBILANT PHARMA

Active Public limited companyfounded 2004active for 22 yearsGuldensporenpark 22, 9820 Merelbeke-MelleKBO/BCE: BE 0865.497.049 subsidiary of JUBILANT PHARMOVA LIMITED
Part of the group JUBILANT PHARMOVA LIMITED 4 companies in 2 countries
See the group

Lifetime

19 annual accounts with figures on one time axis, 21 filings since 2005
peak €17.8m (2010)
€17.7munchanged
lowest -€67,883 (2008)
-€12,772▲ €5,406
peak €17.8m (2010)
€17.6m▼ 0.1%
€86,523▲ 12.7%
Board13 names since 2018all names
5 directorsPerfetti Guiliano and 4 others
Documentsfilings and deeds
06-10-202525 days before the deadline
2025financial year
Loss of €12,772Cash from €1,539 to €362

Key points

from the 2025 annual accounts

Losses

-€274,366 in 19 years
2007-67,88320092011201320152017201920212023-12,7722025

Every financial year from 2007 to 2025 closed with a loss. 2008 was the heaviest.

Payment terms

247 days to suppliers
Suppliers
268 to 247

JUBILANT PHARMA pays its suppliers 21 days earlier than in 2024.

Filings

21 annual accounts 9 days past the deadline
deadline20052010201520202025

2026 accounts not filed: deadline was 31-10-2026.

Checked score

64
Healthy
Financially stronger than 46% of medium-sized companies without a NACE code
Probability in this band: 0.55% to 1.5%
Bankruptcy probability within 12 months
1.4% Low
0%0.5%1.5%4%10%≥ 25%

About 1 in 100 comparable companies go bankrupt within 12 months (an estimate).

Last 24 months 12-2024: 0.2%lowest value 01-2025: 0.2%● unchanged vs 12-2024lowest value 02-2025: 0.2%● unchanged vs 01-2025lowest value 03-2025: 0.2%● unchanged vs 02-2025lowest value 04-2025: 0.3%▲ +0.1 percentage points vs 03-2025 05-2025: 0.3%● unchanged vs 04-2025 06-2025: 0.3%● unchanged vs 05-2025 07-2025: 0.3%● unchanged vs 06-2025 08-2025: 0.3%● unchanged vs 07-2025 09-2025: 0.3%● unchanged vs 08-2025 10-2025: 0.4%▲ +0.1 percentage points vs 09-2025 11-2025: 0.3%▼ -0.1 percentage points vs 10-2025 12-2025: 0.3%● unchanged vs 11-2025 01-2026: 0.3%● unchanged vs 12-2025 02-2026: 0.3%● unchanged vs 01-2026 03-2026: 0.7%▲ +0.4 percentage points vs 02-2026 04-2026: 0.7%● unchanged vs 03-2026 05-2026: 0.7%● unchanged vs 04-2026 06-2026: 0.7%● unchanged vs 05-2026 07-2026: 0.7%● unchanged vs 06-2026 08-2026: 0.8%▲ +0.1 percentage points vs 07-2026 09-2026: 0.9%▲ +0.1 percentage points vs 08-2026 10-2026: 1.3%▲ +0.4 percentage points vs 09-2026 11-2026: 1.4%▲ +0.1 percentage points vs 10-2026highest value

Financial strength
Strong

100=equity 99.5% of total assets
50=short-term debt 0.5% · cash 0.0%
37=return on assets -0.1%

Score breakdown

raises risk
Liquidity: current ratio 0.00, cash €362, halved
1 change of registered office in 24 months
Figures for financial year 2025 (filed on 07-10-2025)
lowers risk
Size: total assets €17.7m
Calculation

The band follows from the bankruptcy probability. 10 more points roughly halve it.

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (no NACE code, medium-sized). It does better than 74% of them on solvency, 35% on liquidity, 39% on profitability and 36% on growth.

The bankruptcy probability was computed on 08-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

The probability rests on the annual accounts with balance sheet date 31-03-2025.

Of the companies with a bankruptcy probability in the low class on 30-06-2025, 0.8% went bankrupt within twelve months.

Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).

Credit verdict

Credit of up to €1,100,000 on 30-day terms is acceptable

Liquidity is insufficient, with a current ratio of 0.0 (0.04 in 2024), below 1. Short-term debt is 0.5% and cash 0% of total assets. 0.5% of the assets are financed with debt and provisions.

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Five signals.
lowers riskraises riskneutral
raises risk · Liquidity: current ratio 0.00, cash €362, halved
NBB · annual accounts
lowers risk · Size: total assets €17.7m
Companies of this size fail less often. How much that weighs depends on the rest of the company's profile.
NBB · annual accounts
raises risk · 1 change of registered office in 24 months
Belgian Official Gazette
raises risk · Figures for financial year 2025 (filed on 07-10-2025)
NBB · annual accounts
neutral · Latest accounts filed on time
The financial year that closed on 31-03-2025 was due by 31-10-2025 and was filed on 06-10-2025, 25 days ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2026
not filed
2025
25 days early
2024
29 days early
2023
4 days early
2022
4 days early
2021
31 days early
2020
2 days early
← before the deadline after the deadline →
tick = median of all Belgian filings

The company filed its last 6 accounts on average 16 days before the deadline. The Belgian median for financial year 2024 was 4 days before the deadline, and 38% of all filings were late.

Searched, nothing found (1)
neutral · No strike-offs in the KBO publications
That holds for every publication since 2021.
KBO publications

Board and ownership

PG
Perfetti Guiliano
Director, since 27-08-2021
DJ
Dr. Jaidev Sanjeev Rajapi
Director, since 15-03-2023
RB
Director, since 15-03-2023
VO
Van Ohlen Michael
Director, since 31-10-2023
VB
Auditor, Bart Roobrouck

Shares in 2 companies, JUBILANT PHARMACEUTICALS and PSI SUPPLY

Board & ownership

Recent changes

Resignation: Giuliano Perfetti (director) Gazette deed
Registered office moved to Merelbeke-Melle New registered office: Guldensporenpark 22 te 9820 Merelbeke-Melle · Previous registered office: Merelbeke · Gazette deed
Registered in the Peppol Directory Reachable for e-invoices through 0208:0865497049
Amendment of the articles General meeting of 06-09-2024 · Gazette deed
All 38 events

Official details

Source: KBO
Status
Active since 27-05-2004Normal situation
Activity
No activity registered in the KBO
Establishment unit
2.137.389.1599820 Merelbeke-Melle, since 28-05-2004
Financial year end
31 March
Peppol
Reachable since 22-12-2025
Company details

Annual accounts to 31-03-2025

€17.7m=
Filing
Filed on 06-10-2025
Financials

Insights on JUBILANT PHARMA

JUBILANT PHARMA has been active since 2004 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €17.6m and a net result of -€12,772.

Equity has been stable since 2019 (±0.1% per year). The computed 12-month bankruptcy probability is 1.4% (low).

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about JUBILANT PHARMA

What is the company number of JUBILANT PHARMA?
The company number of JUBILANT PHARMA is 0865.497.049. The VAT number is the same number with BE in front: BE 0865.497.049.
Where is JUBILANT PHARMA based?
The registered office is at Guldensporenpark 22, 9820 Merelbeke-Melle.Company details
What is the legal form of JUBILANT PHARMA?
JUBILANT PHARMA is a public limited company (NV).
When was JUBILANT PHARMA founded?
JUBILANT PHARMA was founded on 27-05-2004.
Is JUBILANT PHARMA still active?
Yes, JUBILANT PHARMA is an active enterprise in the KBO register.
What is the turnover of JUBILANT PHARMA?
The annual accounts for financial year 2025 state no turnover.Financials
Is JUBILANT PHARMA profitable?
In financial year 2025, JUBILANT PHARMA made a loss of €12,772.
Where can I find the annual accounts of JUBILANT PHARMA?
JUBILANT PHARMA filed 21 annual accounts with the National Bank of Belgium, the latest for financial year 2025.

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.